Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351919 | 0.85 | PARK7 (0.50) | PARK7MAPTALDH1A1SMN1; SMN2PIM1 | |
| SCHEMBL351947 | 0.81 | PARK7 (0.46) | PARK7MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL16650003 | 0.81 | PARK7 (0.43) | PARK7 | |
| Trifluoroacetic Acid SCHEMBL353999 | 0.80 | PARK7 (0.46) | PARK7ALDH1A1 | |
| Dehydroxymethylepoxyquinomicin SCHEMBL14504317 | 0.76 | PARK7 (0.54) | PARK7MAPTALDH1A1SMN1; SMN2 | |
| Dehydroxymethylepoxyquinomicin SCHEMBL1669417 | 0.76 | PARK7 (0.54) | PARK7MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL353845 | 0.73 | PARK7 (0.50) | PARK7MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL352431 | 0.73 | PARK7 (0.56) | PARK7MAPTSMN1; SMN2 | |
| SCHEMBL352816 | 0.71 | PARK7 (0.48) | PARK7ALDH1A1SMN1; SMN2 | |
| SCHEMBL16649950 | 0.71 | PARK7 (0.46) | PARK7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015952-A1 | Inhibitors of NF-KB | PROFECTUS BIOSCIENCES, INC. (US) | 2012-01-19 | — | — | US | claimed |
| US-20120015952-A1 | Inhibitors of NF-KB | PROFECTUS BIOSCIENCES, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015952-A1 | Inhibitors of NF-KB | NFKBIA, IKBKB, IKBKG | PARK7 3327/4885MAPT 2761/4885ALDH1A1 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.